       Document 0665
 DOCN  M9640665
 TI    Natural history of somatic growth in infants born to women infected by
       human immunodeficiency virus. Women and Infants Transmission Study
       Group.
 DT    9604
 AU    Moye J Jr; Rich KC; Kalish LA; Sheon AR; Diaz C; Cooper ER; Pitt J;
       Handelsman E; Pediatric, Adolescent, and Maternal AIDS Branch, National;
       Institute of Child Health and Human Development, National; Institutes of
       Health, Bethesda, MD 20892-7510, USA.
 SO    J Pediatr. 1996 Jan;128(1):58-69. Unique Identifier : AIDSLINE
       MED/96144595
 AB    OBJECTIVE: To evaluate the nature and magnitude of the effect of
       congenitally or perinatally acquired human immunodeficiency virus (HIV)
       infection on somatic growth from birth through 18 months of age. STUDY
       DESIGN: Anthropometry was performed serially in 282 term infants born to
       HIV-infected women in a multicenter prospective natural history cohort
       study. Repeated measures analysis was used to compare z-score
       anthropometric indexes of weight-for-age, length-for-age,
       weight-for-length, and head circumference-for-age between infected and
       uninfected infants, with adjustment for covariates including infant
       gender; maternal education; prenatal alcohol, tobacco, and/or illicit
       drug exposure; and mean prenatal CD4+ T-lymphocyte count. A separate
       repeated measures model was used to assess the effect of infant
       zidovudine treatment on growth. RESULTS: Infants infected with HIV were
       an estimated average 0.28 kg lighter and 1.64 cm shorter than uninfected
       infants at birth, were 0.71 kg lighter and 2.25 cm shorter by 18 months
       of age, and had a sustained estimated average decrement of 0.70 to 0.75
       cm in head circumference. Patterns of growth were similar in male and
       female infants. Infected infants had a progressive decrement in body
       mass index from birth through 6 months of age. Infection with HIV was
       associated with significant decrements across all standardized growth
       outcome measures after adjustment for covariates. Mean z scores were
       lower for weight by 0.612 (p < 0.001), for length by 0.735 (p < 0.001),
       for weight-for-length by 0.255 (p = 0.02), and for head circumference by
       0.563 (p < 0.001) SD units compared with uninfected infants. Zidovudine
       treatment was not associated with improved growth. CONCLUSION: The
       effect of congenitally or perinatally acquired HIV infection on infant
       growth is one of early and progressive decrements in attained linear
       growth and growth in mass, early and sustained decrements in head
       growth, and marked early decrements in body mass index.
 DE    Body Height/PHYSIOLOGY  Body Weight/PHYSIOLOGY  Disease Transmission,
       Vertical  Female  Growth/*PHYSIOLOGY  Head/GROWTH & DEVELOPMENT  Human
       HIV Infections/CONGENITAL/DRUG THERAPY/*PHYSIOPATHOLOGY/  TRANSMISSION
       Infant  Infant, Newborn  Male  Multivariate Analysis  Pregnancy
       *Pregnancy Complications, Infectious  Prospective Studies  Support, U.S.
       Gov't, P.H.S.  Zidovudine/THERAPEUTIC USE  JOURNAL ARTICLE  MULTICENTER
       STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

